"Primary Biliary Cholangitis Clinical Trials"Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis ...

DelveInsight's Primary Sclerosing Cholangitis pipeline report depicts a robust space with 14+ active players working to develop 14+ pipeline therapies for Primary Sclerosing Cholangitis treatment.

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis.

In this study, researchers created a new animal model, the pyogenic spondylodiscitis-posterior fixation model rat, and investigated the mechanism by which posterior fixation suppresses infection.

Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease that affects the bile ducts. About 40% of people will need a liver transplant.

Results A total of 102 patients were diagnosed with brain abscess between January 1994 and April 2009. Median age was 47 years and 65% were male. This yields an estimated incidence of 0,4/100.000 ...

SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree and aid monitoring of patients with primary sclerosing cholangitis, according ...

Linerixibat improved cholestatic pruritus in patients with primary biliary cholangitis, according to phase 3 trial results.

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - Designation based on positive interim analysis of Phase 2b VANTAGE study ...

The FDA has granted accelerated approval to Livdelzi (seladelpar) for primary biliary cholangitis in combination with ursodeoxycholic acid.

The FDA has approved a new treatment for primary biliary cholangitis, an autoimmune liver disease mainly affecting women.